142 related articles for article (PubMed ID: 36997030)
21. Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.
Menguy S; Beylot-Barry M; Parrens M; Ledard AP; Frison E; Comoz F; Battistella M; Szablewski V; Balme B; Croue A; Franck F; Ortonne N; Tournier E; Lamant L; Carlotti A; De Muret A; Le Gall F; Lorton MH; Merlio JP; Vergier B
Histopathology; 2019 Jun; 74(7):1067-1080. PubMed ID: 30715765
[TBL] [Abstract][Full Text] [Related]
22. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
[TBL] [Abstract][Full Text] [Related]
25. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
26. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma.
Xie X; Sundram U; Natkunam Y; Kohler S; Hoppe RT; Kim YH; Cook JR; Hammel J; Swerdlow SH; Guitart J; Smith MD; Bosler D; Listinsky C; Lossos IS; Hsi ED
Mod Pathol; 2008 Jun; 21(6):653-9. PubMed ID: 18264083
[TBL] [Abstract][Full Text] [Related]
27. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
28. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
[TBL] [Abstract][Full Text] [Related]
29. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
[TBL] [Abstract][Full Text] [Related]
30. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
31. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
32. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
33. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
36. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
Petrella T; Copie-Bergman C; Brière J; Delarue R; Jardin F; Ruminy P; Thieblemont C; Figeac M; Canioni D; Feugier P; Fabiani B; Leroy K; Parrens M; André M; Haioun C; Salles GA; Gaulard P; Tilly H; Jais JP; Molina TJ
Ann Oncol; 2017 May; 28(5):1042-1049. PubMed ID: 28327893
[TBL] [Abstract][Full Text] [Related]
37. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
[TBL] [Abstract][Full Text] [Related]
40. Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences.
Felcht M; Klemke CD; Nicolay JP; Weiss C; Assaf C; Wobser M; Schlaak M; Hillen U; Moritz R; Tantcheva-Poor I; Nashan D; Beyer M; Dippel E; Müller CSL; Sachse MM; Meiss F; Géraud C; Marx A; Goerdt S; Geissinger E; Kempf W
J Dtsch Dermatol Ges; 2019 Mar; 17(3):275-285. PubMed ID: 30851152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]